[{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Tyme Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II","graph3":"Eagle Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA receptor A","graph1":"Neurology","graph2":"Phase III","graph3":"Acacia Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.14000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Acacia Pharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Neurology","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Acacia Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Acacia Pharma"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Neurology","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"SymBio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Liquid","sponsorNew":"Eagle Pharmaceuticals \/ SymBio Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ SymBio Pharmaceuticals"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"JPMorgan Chase Bank","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.16,"dosageForm":"Intranasal","sponsorNew":"Eagle Pharmaceuticals \/ JPMorgan Chase Bank","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ JPMorgan Chase Bank"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Acacia Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Acacia Pharma"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Lyophilized powder","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Intravenous infusion","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"AOP Orphan","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Landiolol Hydrochloride","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Combioxin","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CAL02","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Landiolol Hydrochloride","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Par Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eagle Pharmaceuticals \/ Par Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ Par Pharmaceutical"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Amisulpride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Amisulpride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Landiolol Hydrochloride","moa":"ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Enalare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ENA-001","moa":"Potassium ion channel","graph1":"Sleep","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eagle Pharmaceuticals \/ Enalare Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Enalare Therapeutics"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CAL02","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CAL02","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Bendamustine Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eagle Pharmaceuticals \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CAL02","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CAL02","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"||TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Eagle Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
